Tamiflu Articles
Stock Commentary - Tokyo
8 February 2001
Roche plans Tamiflu launch in Japan soon
23 January 2001
Roche names GSK's Abercrombie to heard N Amer pharma ops
12 January 2001
Tamiflu approved in USA for flu in kids
15 December 2000
Roche wins Tamiflu prevention use in USA
21 November 2000
Roche's Tamiflu OKed in Japan
16 November 2000
First human efficacy data with J&J's oral neuraminidase candidate
20 September 2000
Biota gets new Relenza backing from GW
14 September 2000
Roche expects Tamiflu delay in EU
17 August 2000
Roche/Gilead file for Japanese Tamiflu OK
2 August 2000
Roche and Gilead seek pediatric label for TamiFlu
20 June 2000
Pharma sales drive Roche growth in Q1
13 April 2000
No Japanese reimbursement price yet for GW's Relenza
29 March 2000
Roche's TamiFlu, is it "worthwhile?"
24 February 2000
BioCryst enters Phase III with influenza drug
8 February 2000
FDA issues advisory on influenza treatments
19 January 2000
Roche's Tamiflu OKed in Canada
11 January 2000
Busy year for NCEs as major new compound classes launched
6 January 2000
Roche knocked back on TamiFlu ads
30 November 1999
Roche releases Tamiflu prevention data
8 November 1999
Stock Commentary Europe
4 November 1999
Tamiflu approved in the USA
28 October 1999
Influenza drugs battle for supremacy, new prophylaxis data
29 September 1999
Gilead and Roche's flu drug approved in first market, Switzerland
24 September 1999
Stock Commentary New York
23 September 1999
Roche granted Tamiflu priority review
16 September 1999
BioCryst takes off on positive Phase II influenza drug data
27 August 1999
Stock Commentary New York
5 August 1999
- Drug prices to plunge as Indian government announces plans to regulate rates of 652 medicines
- Elan makes "transformational" acquisitions and a divestment
- HIV vaccines: small biotech and government-funded organizations will step in where Big Pharma has fallen short, says analyst
- Is failure to adopt business process management putting the pharma industry at risk?
- Greek research-based drugmaker group AIFD challenges generics assumptions in Draft Patent Law
